339 related articles for article (PubMed ID: 28186088)
1. Current status of immunotherapy for gastrointestinal stromal tumor.
Tan Y; Trent JC; Wilky BA; Kerr DA; Rosenberg AE
Cancer Gene Ther; 2017 Mar; 24(3):130-133. PubMed ID: 28186088
[TBL] [Abstract][Full Text] [Related]
2. The immune system and gastrointestinal stromal tumor: a wealth of opportunities.
Tan Y; Garcia-Buitrago MT; Trent JC; Rosenberg AE
Curr Opin Oncol; 2015 Jul; 27(4):338-42. PubMed ID: 26049274
[TBL] [Abstract][Full Text] [Related]
3. Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies.
Chantharasamee J; Adashek JJ; Wong K; Eckardt MA; Chmielowski B; Dry S; Eilber FC; Singh AS
Curr Treat Options Oncol; 2021 Jan; 22(1):9. PubMed ID: 33400014
[TBL] [Abstract][Full Text] [Related]
4. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
6. Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors.
Roulleaux Dugage M; Jones RL; Trent J; Champiat S; Dumont S
Front Immunol; 2021; 12():715727. PubMed ID: 34489967
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.
Linette GP; Carreno BM
Curr Hematol Malig Rep; 2019 Aug; 14(4):286-291. PubMed ID: 31187421
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Duan J; Wang Y; Jiao S
Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
[TBL] [Abstract][Full Text] [Related]
9. [Targeted therapy combined with immunotherapy in gastrointestinal stromal tumor: a new era of hope and challenges].
Zhao W; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):966-971. PubMed ID: 28900984
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy of Gastrointestinal Stromal Tumors].
Zhu CZ; Liu D; Kang WM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Oct; 41(5):696-701. PubMed ID: 31699203
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
12. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
Darragh LB; Oweida AJ; Karam SD
Front Immunol; 2018; 9():3154. PubMed ID: 30766539
[TBL] [Abstract][Full Text] [Related]
13. Ovarian Cancer Immunotherapy: Turning up the Heat.
Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
[TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
15. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.
Rusakiewicz S; Semeraro M; Sarabi M; Desbois M; Locher C; Mendez R; Vimond N; Concha A; Garrido F; Isambert N; Chaigneau L; Le Brun-Ly V; Dubreuil P; Cremer I; Caignard A; Poirier-Colame V; Chaba K; Flament C; Halama N; Jäger D; Eggermont A; Bonvalot S; Commo F; Terrier P; Opolon P; Emile JF; Coindre JM; Kroemer G; Chaput N; Le Cesne A; Blay JY; Zitvogel L
Cancer Res; 2013 Jun; 73(12):3499-510. PubMed ID: 23592754
[TBL] [Abstract][Full Text] [Related]
16. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
17. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.
Patel SA; Minn AJ
Immunity; 2018 Mar; 48(3):417-433. PubMed ID: 29562193
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
19. The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition.
Varricchi G; Loffredo S; Marone G; Modestino L; Fallahi P; Ferrari SM; de Paulis A; Antonelli A; Galdiero MR
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412566
[TBL] [Abstract][Full Text] [Related]
20. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
Gide TN; Wilmott JS; Scolyer RA; Long GV
Clin Cancer Res; 2018 Mar; 24(6):1260-1270. PubMed ID: 29127120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
